Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors (Q38004855)

26 August 2017

Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors (English)

1 reference

26 August 2017

Anna Maria De Gaetano

1

1 reference

26 August 2017

Vittoria Rufini

2

1 reference

26 August 2017

Paola Castaldi

3

1 reference

26 August 2017

Anna Maria Gatto

4

1 reference

26 August 2017

Laura Filograna

5

1 reference

26 August 2017

Alessandro Giordano

6

1 reference

26 August 2017

Lorenzo Bonomo

7

1 reference

26 August 2017

1 December 2012

1 reference

26 August 2017

1 reference

26 August 2017

37

1 reference

26 August 2017

6

1 reference

26 August 2017

983-1003

1 reference

Positron emission tomography scanning in the evaluation of hepatocellular carcinoma

26 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

FDG PET in the diagnosis of hilar cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

[Gallbladder cancer staging with 18F-FDG PET-CT].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

FDG-PET for the pre-operative evaluation of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Surgery for pancreatic cancer: recent controversies and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

The role of positron emission tomography in the management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Diagnostic usefulness of FDG PET for pancreatic mass lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

The role of PET scanning in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

Comparison of11C-acetate positron emission tomography and67Gallium citrate scintigraphy in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00261-012-9845-Y

10.1007/S00261-012-9845-Y

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference